XML 98 R41.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Other gains and losses, and litigation | 12 Months Ended
--- | ---
Dec. 31, 2024
Analysis of income and expense [abstract] |
Other gains and losses, and litigation | Other gains and losses, and litigation Other gains and losses, and litigation for 2024 represent a charge of €470 millio n, mainly comprising a provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US state of Hawaii (see Note D.22.) For 2023, this line item represented a charge of €196 million related to major litigation. For 2022, this line item represented a charge of €143 million, comprising the pre-tax loss arising on the deconsolidation of EUROAPI (see Note D.1.3.) and costs related to major litigation. Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

X
- References No definition available. + Details
Name: | ifrs-full_AnalysisOfIncomeAndExpenseAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of other gains and losses, and litigation. + References No definition available. + Details
Name: | sny_DisclosureOfOtherGainsAndLossesAndLitigationTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration